NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

病毒載體及質體DNA製造的市場趨勢、市場佔有率、市場規模的預測 (2021-2028年):各媒介型 (AAV、慢病毒)、工作流程、用途、終端用戶產業、疾病區分、地區

Viral Vectors And Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector Type (AAV, Lentivirus), By Workflow, By Application, By End Use, By Disease, By Region, And Segment Forecasts, 2021 - 2028

出版商 Grand View Research, Inc. 商品編碼 1007496
出版日期 內容資訊 英文 300 Pages
商品交期: 2-10個工作天內
價格
病毒載體及質體DNA製造的市場趨勢、市場佔有率、市場規模的預測 (2021-2028年):各媒介型 (AAV、慢病毒)、工作流程、用途、終端用戶產業、疾病區分、地區 Viral Vectors And Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector Type (AAV, Lentivirus), By Workflow, By Application, By End Use, By Disease, By Region, And Segment Forecasts, 2021 - 2028
出版日期: 2021年05月07日內容資訊: 英文 300 Pages
簡介

全球病毒載體及質體DNA製造的市場規模在預測期間內預計以18.8%的年複合成長率發展,成長到2028 年86億美元的規模。

基因治療,病毒載體為基礎的疫苗的強力的開發平台等要素促進該市場的成長。

本報告提供全球病毒載體及質體DNA製造的市場調查,市場定義和概要,價值鏈,新型冠狀病毒感染疾病 (COVID-19)以及其他的市場影響因素分析,市場規模的變化、預測,媒介、工作流程、用途、終端用戶、疾病區分等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

第1章 摘要整理

第2章 調查手法

第3章 市場可變因素、趨勢、展望

  • 市場分類、範圍
  • 市場動態
  • COVID-19:影響分析
  • 病毒載體的生產: 各階段的課題、解決方案
  • 普及、成長預測製圖
  • 波特分析
  • SWOT分析
  • 廠商形勢
  • 生產能力製圖
  • 組合的企業的清單
  • 媒介廠商一覽

第4章 病毒載體的生產: 成本

第5章 病毒載體的生產、產量分析

第6章 病毒載體的製造: 流程的經濟考察、課題

第7章 病毒載體製造市場: 策略性聯盟

第8章 市場預測、趨勢分析:各媒介型

  • 腺病毒
  • 反轉錄病毒
  • 腺結合病毒 (AAV)
  • 慢病毒
  • 質體DNA
  • 其他

第9章 市場預測、趨勢分析:各工作流程

  • 上游處理
  • 下游處理

第10章 市場預測、趨勢分析:各用途

  • 反義、RNAi 療法
  • 基因治療
  • 細胞治療
  • 疫苗
  • 研究

第11章 市場預測、趨勢分析:各終端用戶

  • 製藥、生物醫藥品企業
  • 研究機關

第12章 市場預測、趨勢分析:各疾病種類

  • 癌症
  • 遺傳性疾病
  • 感染疾病
  • 其他
目錄
Product Code: GVR-2-68038-695-0

Viral Vectors And Plasmid DNA Manufacturing Market Growth & Trends

The global viral vectors and plasmid DNA manufacturing market size is expected to reach USD 8.6 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 18.8% from 2021 to 2028. The robust pipeline for gene therapies and viral-vector-based vaccines has primarily driven the market.

Amidst the COVID-19 pandemic, the demand for viral vectors has rapidly increased especially in vaccinology. This led to expanding manufacturing capabilities by operating players to meet the growing demand. The application of these vectors in vaccine development has witnessed significant growth in 2020.

Also, an increase in the number of gene therapy-based discovery programs initiated by biotechnology and pharmaceutical companies is expected to drive the demand for scalable production of gene therapy vectors. Owing to this, several private and public agencies are providing funds to accelerate advancements in the manufacturing processes for viral vectors.

Besides, the implementation of single-use technology can lead to significant savings in capital, operating costs, materials, and labor. The use of this equipment will enhance efficiency and improve flexibility, leading to high yields of the final product. Thus, advancements in single-use technology directly impact revenue growth in this space.

Viral Vectors And Plasmid DNA Manufacturing Market Report Highlights

The Adeno Associated Virus (AAV) segment accounted for the significant revenue share in 2020. High usage and promising results in gene therapy clinical trials have boosted its adoption

Moreover, several biopharma companies are offering their viral vector platform for the development of AAV-based gene therapy products, thereby driving the segment

The downstream processing segment dominated the market in terms of revenue share. This can be attributed to the availability of advanced purification products

Owing to the rising demand for cost-effective and scalable manufacturing processes, companies are involved in the development of the upstream cell culture processes

This is anticipated to result in the notable growth of the upstream processing segment

The vaccinology segment dominated the market in terms of revenue share in 2020

The SARS-COV-2 pandemic has supplemented the use of vectors in this segment

With the active engagement of the research community in the R&D of advanced therapies, research institutes captured the maximum revenue share in the market

The initiation of several R&D programs by pharmaceutical and biopharmaceutical companies to combat the COVID-19 crisis would further propel market growth

A rapidly growing pipeline of advanced therapy products for various cancer types has led to lucrative revenue generation in the cancer segment

North America maintained its dominance in 2020 owing to the high number of entities engaged in offering products and services for viral vector manufacturing in the U.S.

Furthermore, the remarkable success of viral vector-based Kymriah, Yescarta, and ZOLGENSMA in the U.S. has also contributed to regional dominance

In Asia Pacific, the market is projected to witness the fastest growth rate owing to industrialization and clinical transformation of gene therapy in the region

Companies continue to make focused attempts to expand their manufacturing facilities as well as service portfolio to maintain their market presence

Table of Contents

Chapter 1 Executive Summary

  • 1.1. Market Summary

Chapter 2 Research Methodology

  • 2.1 Information Procurement
  • 2.2 Information or Data Analysis
  • 2.3 Market Model
    • 2.3.1 Market analysis, by vector type
      • 2.3.1.1 By characteristics/advantage & disadvantage
      • 2.3.1.2 By clinical trials
      • 2.3.1.3 By manufacturing service penetration/availability
    • 2.3.2 Market study, by end use
    • 2.3.3 Regional analysis

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Market Segmentation & Scope
  • 3.2 Market Dynamics
    • 3.2.1 Market drivers analysis
      • 3.2.1.1 Robust pipeline for gene therapies and viral vector vaccines
      • 3.2.1.2 Technological advancemnets in manufacturing vectors
      • 3.2.1.3 HIghly competitive market and various strategies undertaken by market entities
    • 3.2.2 Market restraint analysis
      • 3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy and viral vectors
    • 3.2.3 Market challenge analysis
      • 3.2.3.1 Production capacity challenges
      • 3.2.3.2 Manufacturing challenges pertaining to large scale production of vectors
    • 3.2.4 Market opportunity Analysis
      • 3.2.4.1 Facility expansion for cell and gene therapies
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Viral Vector Production: Stepwise Challenges & Solutions
    • 3.4.1 Host cell production & banking Needs
    • 3.4.2 Viral vector production, Fill & Finish: challenges & solutions
    • 3.4.3 Viral vector production, analytics: challenges & solutions
  • 3.5 Penetration & Growth Prospect Mapping for Vector Type, 2020
  • 3.6 Industry Analysis - Porter's
  • 3.7 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • 3.8 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2020
  • 3.9 Manufacturer's Landscape
  • 3.10 Viral Vector Production Capacity Mapping Analysis
    • 3.10.1 North America: capacity & service mapping
    • 3.10.2 Europe: capacity & service mapping
      • 3.10.2.1 Cobra Biologics (Sweden and the U.K.)
      • 3.10.2.2 Biovian (Finland)
      • 3.10.2.3 Oxford Biomedica (U.K.)
      • 3.10.2.4 Lonza Pharma & Biotech (The Netherlands)
      • 3.10.2.5 FinVector Oy (Finland)
      • 3.10.2.6 Fujifilm Diosynth Biotechnologies (Denmark)
      • 3.10.2.7 Fujifilm Diosynth Biotechnologies (U.K.)
      • 3.10.2.8 Catalent Inc. (Belgium)
      • 3.10.2.9 Novasep (Belgium)
      • 3.10.2.10 Exothera (Belgium)
      • 3.10.2.11 Delphi Genetics SA (Belgium)
      • 3.10.2.12 Yposkesi (France)
      • 3.10.2.13 VIVEbiotech (Spain)
      • 3.10.2.14 MolMed SpA (Italy)
      • 3.10.2.15 Anemocyte (Italy)
  • 3.11 List of Companies with Portfolio Comprising Vector-based Therapeutic Candidates
  • 3.12 List of Vector Manufacturers

Chapter 4 Viral Vector Production: Costs

  • 4.1 Cost Models for Viral Vector Production
    • 4.1.1 Campaign model
    • 4.1.2 Day rate model
    • 4.1.3 Hybrid model
  • 4.2 Viral Vector Manufacturing Pricing Analysis
    • 4.2.1 Parameters affecting price
    • 4.2.2 AAV: Pricing analysis
    • 4.2.3 Lentivirus: Pricing analysis
    • 4.2.4 Adenovirus: Pricing analysis
    • 4.2.5 Retrovirus: Pricing analysis
    • 4.2.6 Plasmid: Pricing analysis
    • 4.2.7 Gene Synthesis Cost
    • 4.2.8 Genes/ Gene Fragment Cost Analysis

Chapter 5 Viral Vector Production & Yield Analysis

  • 5.1 Production Yields: Biomarin, Spark Therapeutics & Solid Biosciences
  • 5.2 Various Modes of Vector Production to increase & achieve Target Doses
    • 5.2.1 Adenoviral vectors
    • 5.2.2 Gamma- retroviral (MLV - murineleukemia virus) vectors
    • 5.2.3 Lentiviral vectors
    • 5.2.4 AAV vectors
    • 5.2.5 rAAV vectors
      • 5.2.5.1 rAAV Production: challenges & solutions
  • 5.3 Total vector quantity produced per day and yield volume using different cell culture systems
  • 5.4 Measures undertaken to optimize manufacturing of viral vectors for cell and gene therapy
  • 5.5 Analysis of large- and small-scale production of viral vectors based on batch size
    • 5.5.1 Small-scale/laboratory-scale cell culture systems
    • 5.5.2 Large-scale cell culture systems
  • 5.6 Common Practices for Small-Scale (10-50L) Adenovirus Vector Manufacturing

Chapter 6 Viral Vector Manufacturing: Process Economic Considerations & Challenges

  • 6.1. Technological Advances in Manufacturing
    • 6.1.1. Stable producer cell lines
    • 6.1.2 Transient production
    • 6.1.3 Lentiviral vector production process
      • 6.1.3.1 Developments in LentiVector platform
  • 6.2 CoGs Analysis of the Baseline Process
    • 6.2.1 Raw material
    • 6.2.2 Labor costs
    • 6.2.3 Process costs
  • 6.3 Regulatory Expectations
  • 6.4 Approaches for Viral Vector Supply Gene Therapy
    • 6.4.1 Gene therapy manufacturing facilities: trends & types
    • 6.4.2 Gene therapy road map: key external trends

Chapter 7 Viral Vector Manufacturing Market: Strategic Alliances

  • 7.1 Is The Time Right To Invest In Gene Therapy Sector?
  • 7.2 Strategic Approaches for Market Scale-Up
    • 7.2.1 Partnership models
    • 7.2.2 Acquisition
    • 7.2.3 Minority interest (ownership)
    • 7.2.4 Joint venture
    • 7.2.5 Alliance
    • 7.2.6 Franchise
  • 7.3 Collaborations in Viral Vector Manufacturing Market
    • 7.3.1 Breakthrough growth: Lonza, Oxford Biomedica & others

Chapter 8 Vector Type Business Analysis

  • 8.1 Market: Vector Type Movement Analysis
  • 8.2 Adenovirus
    • 8.2.1 Global adenovirus market, 2017 - 2028 (USD Million)
  • 8.3 Retrovirus
    • 8.3.1 Global retrovirus market, 2017 - 2028 (USD Million)
  • 8.4 Adeno-associated Virus (AAV)
    • 8.4.1 AAV manufacturing: Operating CROs & CMOs/CDMOs
    • 8.4.2 Global AAV market, 2017 - 2028 (USD Million)
  • 8.5 Lentivirus
    • 8.5.1 Global lentivirus market, 2017 - 2028 (USD Million)
  • 8.6 Plasmid DNA
    • 8.6.1 Global plasmid DNA market, 2017 - 2028 (USD Million)
  • 8.7 Others
    • 8.7.1 Global other vectors market, 2017 - 2028 (USD Million)

Chapter 9 Workflow Business Analysis

  • 9.1 Market: Workflow Movement Analysis
  • 9.2 Upstream Processing
    • 9.2.1 Market estimates and forecast, 2017 - 2028 (USD Million)
    • 9.2.2 Vector amplification and expansion
      • 9.2.2.1 Market estimates and forecast, 2017 - 2028 (USD Million)
    • 9.2.3 Vector recovery/harvesting
      • 9.2.3.1 Market estimates and forecast, 2017 - 2028 (USD Million)
  • 9.3 Downstream Processing
    • 9.3.1 Market estimates and forecast, for 2017 - 2028 (USD Million)
    • 9.3.2 Purification
      • 9.3.2.1 Market estimates and forecast, 2017 - 2028 (USD Million)
    • 9.3.3 Fill finish
      • 9.3.3.1 Market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 10 Application Business Analysis

  • 10.1 Market: Application Movement Analysis
  • 10.2 Antisense & RNAi Therapy
    • 10.2.1 Market for antisense, & RNAi therapy, 2017 - 2028 (USD Million)
  • 10.3 Gene Therapy
    • 10.3.1 Market for gene therapy, 2017 - 2028 (USD Million)
  • 10.4 Cell Therapy
    • 10.4.1 Market for cell therapy, 2017 - 2028 (USD Million)
  • 10.5 Vaccinology
    • 10.5.1 Market for vaccinology, 2017 - 2028 (USD Million)
  • 10.6 Research Applications
    • 10.6.1 Market for research applications, 2017 - 2028 (USD Million)

Chapter 11 End-use Business Analysis

  • 11.1 Market: End-use Movement Analysis
  • 11.2 Pharmaceutical and Biopharmaceutical Companies
    • 11.2.1 Market for pharmaceutical and biopharmaceutical companies, 2017 - 2028 (USD Million)
  • 11.3 Research Institutes
    • 11.3.1 Market for research institutes, 2017 - 2028 (USD Million)

Chapter 12 Disease Business Analysis

  • 12.1 Market: Disease Movement Analysis
  • 12.2 Cancer
    • 12.2.1 Market for cancer, 2017 - 2028 (USD Million)
  • 12.3 Genetic Disorders
    • 12.3.1 Market for genetic disorders, 2017 - 2028 (USD Million)
  • 12.4 Infectious Diseases
    • 12.4.1 Market for infectious diseases, 2017 - 2028 (USD Million)
  • 12.5 Other Diseases
    • 12.5.1 Market for other diseases, 2017 - 2028 (USD Million)

List of Tables

  • Table 1 Viral vector-based COVID-19 vaccine candidates
  • Table 2 Operating CMOs/CDMOs for advanced therapy manufacturing in EU
  • Table 3 Contract Manufacturing Organizations (CMOs) offering viral & non-viral vector manufacturing services
  • Table 4 Biozilla, LLC's plasmid purification cost
  • Table 5 AAV production: Pricing analysis
  • Table 6 AAV packaging, cloning, & titration: Pricing analysis
  • Table 7 Lentivirus production: Pricing analysis
  • Table 8 Lentivirus packaging, titration, & others: Pricing analysis
  • Table 9 Adenovirus production: Pricing analysis
  • Table 10 Adenovirus packaging, titration, & others: Pricing analysis
  • Table 11 Retrovirus production: Pricing analysis
  • Table 12 Plasmid production: Pricing analysis
  • Table 13 Plasmid DNA purification: Pricing analysis
  • Table 14 Eurofins Genomics LLC's gene synthesis cost analysis
  • Table 15 GenScript's gene synthesis cost analysis (GenPlus Economy Gene Synthesis)
  • Table 16 Eurofins Genomics LLC's gene fragments cost analysis
  • Table 17 Production yields of rAAV vectors using different production systems
  • Table 18 Large-scale production of MLV vectors for clinical applications
  • Table 19 Most-used 2D devices used for LV production
  • Table 20 Fixed-bed bioreactors optimized for high-scale LV production
  • Table 21 Overview of costs involved in cell therapy development
  • Table 22 Common raw/starting materials for viral vector manufacturing
  • Table 23 Sensitivity of baseline process to failure rates during cell therapy production
  • Table 24 AAV services of Vigene
  • Table 25 List of CROs & CMOs/CDMOs operating in the AAV market in the U.S.
  • Table 26 Human clinical trials in progress with viral vectored vaccines
  • Table 27 Clinical trials in cancer gene therapy
  • Table 28 List of key technology supplier for downstream processing
  • Table 29 List of key technology supplier for upstream processing
  • Table 30 Distributors list for Sartorius for key countries
  • Table 31 Distributors list for Cytiva for key countries
  • Table 32 List of key emerging companies
  • Table 33 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 34 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 35 North America upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 36 North America downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 37 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 38 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 39 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 40 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 41 U.S.viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 42 U.S. upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2017 - 2028 (USD Million)
  • Table 43 U.S. downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 44 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 45 U.S.viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 46 U.S.viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 47 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 48 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 49 Canada upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2017 - 2028 (USD Million)
  • Table 50 Canada downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 51 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 52 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 53 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 54 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 55 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 56 Europe upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 57 Europe downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 58 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 59 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 60 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 61 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 62 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 63 U.K. upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 64 U.K. downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 65 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 66 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 67 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 68 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 69 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 70 Germany upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 71 Germany downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 72 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 73 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 74 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 75 France viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 76 France viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 77 France upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 78 France downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 79 France viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 80 France viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 81 France viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 82 Italy viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 83 Italy viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 84 Italy upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 85 Italy downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 86 Italy viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 87 Italy viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 88 Italy viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 89 Spain viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 90 Spain viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 91 Spain upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 92 Spain downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 93 Spain viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 94 Spain viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 95 Spain viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 96 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 97 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 98 Asia Pacific upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 99 Asia Pacific downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 100 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 101 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 102 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 103 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 104 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 105 China upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 106 China downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 107 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 108 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 109 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 110 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 111 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 112 Japan upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 113 Japan downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 114 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 115 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 116 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 117 India viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 118 India viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 119 India upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 120 India downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 121 India viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 122 India viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 123 India viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 124 South Korea viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 125 South Korea viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 126 South Korea upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 127 South Korea downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 128 South Korea viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 129 South Korea viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 130 South Korea viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 131 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 132 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 133 Latin America upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 134 Latin America downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 135 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 136 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 137 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 138 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 139 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 140 Brazil upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 141 Brazil downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 142 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 143 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 144 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 145 Mexico viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 146 Mexico viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 147 Mexico upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 148 Mexico downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 149 Mexico viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 150 Mexico viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 151 Mexico viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 152 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 153 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 154 MEA upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 155 MEA downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 156 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 157 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 158 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 159 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 160 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 161 South Africa upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 162 South Africa downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 163 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 164 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 165 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)
  • Table 166 Saudi Arabia viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2017 - 2028 (USD Million)
  • Table 167 Saudi Arabia viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • Table 168 Saudi Arabia upstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow 2017 - 2028 (USD Million)
  • Table 169 Saudi Arabia downstream processing-based viral vector & plasmid DNA manufacturing market estimates & forecasts by workflow, 2017 - 2028 (USD Million)
  • Table 170 Saudi Arabia viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • Table 171 Saudi Arabia viral vector & plasmid DNA manufacturing market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • Table 172 Saudi Arabia viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2017 - 2028 (USD Million)

List of Figures

  • Fig. 1 Market snapshot, 2020 (USD Million)
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research process
  • Fig. 5 Primary research validation
  • Fig. 6 Market research approaches
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD modeling
  • Fig. 9 Market formulation & validation
  • Fig. 10 Vector type characteristic analysis
  • Fig. 11 QFD model assessment for vector type
  • Fig. 12 Vector type characteristic analysis
  • Fig. 13 Lentiviral vectors versus AAV vectors
  • Fig. 14 Global number of AAV- and lentivirus-based clinical trials
  • Fig. 15 Gene therapy approvals versus clinical trials
  • Fig. 16 Some major industry sponsors of CAR T cell clinical trials, as of September 2019
  • Fig. 17 Distribution of the sponsors of advanced therapies clinical trials, 2016
  • Fig. 18 Distribution of noncommercial sponsors of ATMP clinical trials, 2016
  • Fig. 19 Gene therapy approvals versus clinical trials
  • Fig. 20 Penetration by end use settings
  • Fig. 21 Regional analysis for rare disease genetic testing market
  • Fig. 22 U.K. cell and gene therapy manufacturing capacity, 2016 to 2019
  • Fig. 23 Number of gene therapy sites across gene therapy and multifunctional facilities in the U.K., 2019
  • Fig. 24 Market trends & outlook
  • Fig. 25 Market segmentation & scope
  • Fig. 26 Market driver relevance analysis (Current & future impact)
  • Fig. 27 Gene therapy clinical trials
  • Fig. 28 Viral vectors used in clinical trials
  • Fig. 29 Key strategies by market players to drive success in gene therapy arena
  • Fig. 30 Recent and upcoming approved gene transfer-mediated programs
  • Fig. 31 Market restraint relevance analysis (Current & future impact)
  • Fig. 32 Various ethical questions raised by gene therapy
  • Fig. 33 Major challenges in large-scale vector manufacturing
  • Fig. 34 Plasmid production: Challenges & solutions
  • Fig. 35 Host cell production & banking needs
  • Fig. 36 Viral vector production, F&F: challenges & solutions
  • Fig. 37 Viral vector production, analytics: Challenges & solutions
  • Fig. 38 Penetration & growth prospect mapping for vector type, 2020
  • Fig. 39 Porter's Five Forces Analysis
  • Fig. 40 SWOT analysis, by factor (Political & Legal, Economic and Technological)
  • Fig. 41 Penetration & growth prospect mapping for prominent industry players, 2020
  • Fig. 42 Viral Vector Manufacturing Landscape
  • Fig. 43 List of companies with portfolio comprising vector-based therapeutic candidates
  • Fig. 44 List of vector manufacturers
  • Fig. 45 Comparison of costs estimated by campaign, day rate, and hybrid models
  • Fig. 46 Campaign model for viral vector production
  • Fig. 47 Day rate model for viral vector production
  • Fig. 48 Hybrid model for viral vector production
  • Fig. 49 VIRAL VECTOR PRODUCTION UNIT's AAV production cost by application
  • Fig. 50 Kerafast, Inc.'s lentivirus production cost by titer
  • Fig. 51 Comparative analysis: Biozilla's service vs. commercial kit
  • Fig. 52 Company-wise: Vector yields
  • Fig. 53 Prevailing Technologies for AAV Production
  • Fig. 54 rAAV Production: Challenges & Solutions
  • Fig. 55 iCELLis systems: Productivities
  • Fig. 56 Small- & large-scale cell culture systems for production of viral vectors
  • Fig. 57 Process flow diagram for common practices for small-scale (10-50 L) adenoviral vector purification
  • Fig. 58 Breakdown of CoGs per process for cell therapy manufacture
  • Fig. 59 Progression of cGMP compliance at different product development stages
  • Fig. 60 Standardization & Regulatory Challenges
  • Fig. 61 Gene Therapy Manufacturing Facilities: Trends & Types
  • Fig. 62 Gene Therapy Road Map: Key External Trends
  • Fig. 63 Strategic Approaches for Market Scale-Up
  • Fig. 64 Viral vector & plasmid DNA manufacturing market: Vector type outlook key takeaways
  • Fig. 65 Viral vector & plasmid DNA manufacturing market: Vector type movement analysis
  • Fig. 66 Global adenovirus market, 2017 - 2028 (USD Million)
  • Fig. 67 Global Retrovirus market, 2017 - 2028 (USD Million)
  • Fig. 68 Global AAV market, 2017 - 2028 (USD Million)
  • Fig. 69 Global Lentivirus market, 2017 - 2028 (USD Million)
  • Fig. 70 Global Plasmid DNA market, 2017 - 2028 (USD Million)
  • Fig. 71 Global Other vectors market, 2017 - 2028 (USD Million)
  • Fig. 72 Viral vector & plasmid DNA manufacturing market : Workflow outlook and key takeaways
  • Fig. 73 Global viral vector & plasmid DNA manufacturing market: Workflow movement analysis
  • Fig. 74 Global upstream processing market estimates and forecast 2017 - 2028 (USD Million)
  • Fig. 75 Global vector amplification and expansion market estimates and forecast 2017 - 2028 (USD Million)
  • Fig. 76 Global vector recovery/harvesting market estimates and forecast 2017 - 2028 (USD Million)
  • Fig. 77 Global downstream processing market estimates and forecast, for 2017 - 2028 (USD Million)
  • Fig. 78 Global purification market estimates and forecast 2017 - 2028 (USD Million)
  • Fig. 79 Global fill finish market estimates and forecast 2017 - 2028 (USD Million)
  • Fig. 80 Viral vector & plasmid DNA manufacturing market : Application outlook and key takeaways
  • Fig. 81 Viral vector & plasmid DNA manufacturing market: Application movement analysis
  • Fig. 82 Global viral vector & plasmid DNA manufacturing market for antisense & RNAi therapy, 2017 - 2028 (USD Million)
  • Fig. 83 Percentage of viral vector in gene therapy clinical trials as of April 2019
  • Fig. 84 Global viral vector & plasmid DNA manufacturing market for gene therapy, 2017 - 2028 (USD Million)
  • Fig. 85 Global viral vector & plasmid DNA manufacturing market for cell therapy, 2017 - 2028 (USD Million)
  • Fig. 86 Strengths and weaknesses of viral vector vaccines
  • Fig. 87 Global viral vector & plasmid DNA manufacturing market for vaccinology, 2017 - 2028 (USD Million)
  • Fig. 88 Global viral vector & plasmid DNA manufacturing market for research applications, 2017 - 2028 (USD Million)
  • Fig. 89 Viral vector & plasmid DNA manufacturing market : End-use outlook and key takeaways
  • Fig. 90 Global viral vector & plasmid DNA manufacturing market: End-use movement analysis
  • Fig. 91 Global viral vector & plasmid DNA manufacturing market for pharmaceutical and biopharmaceutical companies, 2017 - 2028 (USD Million)
  • Fig. 92 Global viral vector & plasmid DNA manufacturing market for research institutes, 2017 - 2028
  • Fig. 93 Viral vector & plasmid DNA manufacturing market : Disease outlook and key takeaways
  • Fig. 94 Global viral vector & plasmid DNA manufacturing market: Disease movement analysis
  • Fig. 95 Global viral vector & plasmid DNA manufacturing market for cancer, 2017 - 2028 (USD Million)
  • Fig. 96 Global viral vector & plasmid DNA manufacturing market for genetic disorders, 2017 - 2028 (USD Million)
  • Fig. 97 Global viral vector & plasmid DNA manufacturing market for infectious diseases, 2017 - 2028 (USD Million)
  • Fig. 98 Global viral vector & plasmid DNA manufacturing market for other diseases, 2017 - 2028 (USD Million)
  • Fig. 99 Regional marketplace: Key takeaway
  • Fig. 100 Viral vector & plasmid DNA manufacturing market: Regional movement analysis
  • Fig. 101 North America viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 102 U.S. viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 103 Canada viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 104 Europe viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 105 U.K. viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 106 Germany viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 107 France viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 108 Italy viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 109 Spain viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 110 Asia Pacific viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 111 China viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 112 Japan viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 113 India viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 114 South Korea viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 115 Latin America viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 116 Brazil viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 117 Mexico viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 118 MEA viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 119 South Africa viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 120 Saudi Arabia viral vector & plasmid DNA manufacturing market, 2017 - 2028 (USD Million)
  • Fig. 121 New developments-based initiatives by key market participants
  • Fig. 122 Impact analysis of new developments by key market participants
  • Fig. 123 Company/competition categorization
  • Fig. 124 Distribution by location of manufacturing facility
  • Fig. 125 CDMOs operating in China
  • Fig. 126 Distribution by scale of production
  • Fig. 127 Company mapping analysis, by manufacturing facility, type of organization, and purpose of production
  • Fig. 128 Key public companies: Heat map analysis
  • Fig. 129 List of companies with portfolio comprising antibody & viral vector-based therapeutic candidates
  • Fig. 130 Synergy analysis: Major deals & strategic alliances
  • Fig. 131 Participant categorization
  • Fig. 132 Strategy framework
  • Fig. 133 SWOT analysis: Merck
  • Fig. 134 SWOT analysis: Lonza
  • Fig. 135 SWOT analysis: FUJIFILM
  • Fig. 136 SWOT analysis: Cobra Biologics
  • Fig. 137 SWOT analysis: Brammer Bio
  • Fig. 138 SWOT analysis: Waisman Biomanufacturing
  • Fig. 139 SWOT analysis: Genezen
  • Fig. 140 SWOT analysis: YPOSKESI
  • Fig. 141 SWOT analysis: ABL Inc.
  • Fig. 142 SWOT analysis: Novasep Holding S.A.S
  • Fig. 143 SWOT analysis: Orgenesis Biotech Israel Ltd
  • Fig. 144 SWOT analysis: Vigene Biosciences
  • Fig. 145 SWOT analysis: GE Healthcare
  • Fig. 146 SWOT analysis: Cevec Pharmaceuticals GmbH
  • Fig. 147 SWOT analysis: Batavia Biosciences
  • Fig. 148 SWOT analysis: Biovion
  • Fig. 149 SWOT analysis: Wuxi AppTec Co Ltd.
  • Fig. 150 SWOT analysis: VGXI Inc.
  • Fig. 151 SWOT analysis: Paragon Servicest Inc.
  • Fig. 152 SWOT analysis: Lentigen Technology
  • Fig. 153 SWOT analysis: Sirion Biotech GmbH
  • Fig. 154 SWOT analysis: Virovek Incorporation
  • Fig. 155 SWOT analysis: BioNTech
  • Fig. 156 SWOT analysis: VIVEbiotech
  • Fig. 157 SWOT analysis: Creative Biogene
  • Fig. 158 SWOT analysis: Vibalogics GmbH
  • Fig. 159 SWOT analysis: Takara BioInc.
  • Fig. 160 SWOT analysis: Cell and Gene Therapy Catapult
  • Fig. 161 SWOT analysis: Bluebird Bio Inc.
  • Fig. 162 SWOT analysis: Addgene Inc.
  • Fig. 163 SWOT analysis: Aldevron LLC
  • Fig. 164 SWOT analysis: Audentis
  • Fig. 165 SWOT analysis: BioMarin Pharmaceuticals
  • Fig. 166 SWOT analysis: REGENXBIO Inc.